Tyra Biosciences Expands Leadership Team with Key Appointments

In a significant move aimed at bolstering its development efforts in precision medicines, Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology firm, has appointed Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer. These appointments come at a critical juncture for the company as it progresses its clinical programs targeting key areas in FGFR (Fibroblast Growth Factor Receptor) biology.

Strategic Appointments

Effective immediately, Bhavesh Ashar will step into the role of COO, while Heather Faulds will officially join on December 8, 2025. Both leaders bring extensive experience in biotechnology and pharmaceuticals, positioning Tyra to better navigate the complex regulatory landscape and expedite the development of its innovative products.

Ashar boasts a robust background with over 25 years in the pharmaceutical sector, having most recently served as Chief Commercial Officer at SpringWorks Therapeutics. There, he was instrumental in launching two prominent oncology products, helping to establish successful commercial strategies prior to the company’s acquisition by Merck KGaA.

On the other hand, Faulds has over 20 years of expertise in global regulatory strategies and has been pivotal in obtaining numerous drug approvals across various therapeutic areas. Her previous role as Senior Vice President of Global Regulatory Sciences at Blueprint Medicines further solidifies her qualifications.